%20--%3e%3csvg%20width='63.297821mm'%20height='39.29665mm'%20viewBox='0%200%2063.297821%2039.29665'%20version='1.1'%20id='svg8765'%20inkscape:version='1.1%20(c4e8f9ed74,%202021-05-24)'%20sodipodi:docname='OBALogoSingle2.svg'%20xmlns:inkscape='http://www.inkscape.org/namespaces/inkscape'%20xmlns:sodipodi='http://sodipodi.sourceforge.net/DTD/sodipodi-0.dtd'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:svg='http://www.w3.org/2000/svg'%3e%3csodipodi:namedview%20id='namedview8767'%20pagecolor='%23ffffff'%20bordercolor='%23666666'%20borderopacity='1.0'%20inkscape:pageshadow='2'%20inkscape:pageopacity='0.0'%20inkscape:pagecheckerboard='0'%20inkscape:document-units='mm'%20showgrid='false'%20fit-margin-top='0'%20fit-margin-left='0'%20fit-margin-right='0'%20fit-margin-bottom='0'%20inkscape:zoom='1.1759259'%20inkscape:cx='179.85827'%20inkscape:cy='102.04724'%20inkscape:window-width='1920'%20inkscape:window-height='972'%20inkscape:window-x='0'%20inkscape:window-y='27'%20inkscape:window-maximized='1'%20inkscape:current-layer='layer1'%20/%3e%3cdefs%20id='defs8762'%20/%3e%3cg%20inkscape:label='Layer%201'%20inkscape:groupmode='layer'%20id='layer1'%20transform='translate(-31.351095,-50.101677)'%3e%3cpath%20style='fill:none;stroke:%233584e4;stroke-width:3.965;stroke-linecap:square;stroke-linejoin:round;stroke-miterlimit:4;stroke-dasharray:none;stroke-opacity:1'%20d='m%2077.07508,77.78787%2014.84134,8.87817%20V%2052.83397%20L%2034.08359,86.5521%20V%2053.69366%20l%2015.27351,9.31107'%20id='path8388'%20sodipodi:nodetypes='cccccc'%20/%3e%3c/g%3e%3c/svg%3e)
Stock USHQLNYSEFinancial ServicesDividend King
Tekla Life Sciences Investors(HQL) Stock Analysis | Financial Services
USD --+0.00%
Reward68High
Risk30Moderate
75%Data
Strong 17857% profit margin · 10.6% dividend yield · Revenue down 61% YoY
USD —+0.00 (+0.00%) Previous close · NYSE
Market Performance
Stock returned +10.0% over the past year, broadly in line with market conditions.What is Tekla Life Sciences Investors?
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc.
The brief on Tekla Life Sciences Investors
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
What is Tekla Life Sciences Investors?
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. The company is listed on the NYSE in USA, operating in the Financial Services sector, with a market capitalisation of 544.91M, and a P/E ratio of 2.7x.
Financial Highlights
Investment Breakdown
Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Adequate profitability with some margin variability in recent periods.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation appears fair relative to current fundamentals.
Analysis
Reward: High (68)Similar stocks to compare
A short list of Asset Management names that are close enough in size to make side-by-side comparison useful.
Company Information
SectorFinancial Services
IndustryAsset Management
Market Cap544.91M
P/E Ratio2.6702
Dividend Yield10.64%
Beta0.729
Insider Activity
12M windowQuiet
Fewer than three real open-market insider trades in the last 12 months. Mechanical activity (option exercises, RSU vests) is excluded from the signal.